Showing Form 4 filings for GRCE
Pre-configured institutional-grade criteria for instant high-conviction screening
Multiple insiders buying stock within the last 30 days
Direct open-market purchases by Chief Executive Officers
Financial chiefs and top corporate officers accumulating shares
Institutional-scale insider purchases of $1,000,000 or greater
Insiders increasing their overall equity ownership by over 20%
High-value executive divestments by CEOs and CFOs over $1M
Grace Therapeutics, Inc.
Price
$1.74
Shares
48,060
Ownership
3,102,904
Value/Share
Opaleye Management Inc.
10%
Unknown
Industry
$1.92
71,065
2,944,354